NCT02400320 is a Phase 4 clinical trial of Topical Spray in Skin Irritation, sponsored by GlaxoSmithKline.

Who is sponsoring NCT02400320?

NCT02400320 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT02400320?

Interventions in NCT02400320: Topical Spray, Topical Gel, Saline.

What condition does NCT02400320 study?

NCT02400320 studies Skin Irritation.

Is NCT02400320 still recruiting?

NCT02400320 is currently withdrawn. Last updated 12 September 2017.

Last reviewed 2017-09-12 · How we verify

NCT02400320

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Local Skin Safety Study of a Topical Pain Relief Spray Containing a Combination of Diclofenac, Methyl Salicylate, and Menthol

Withdrawn Phase 4 Last updated 12 September 2017

What this trial tests

Phase 4 trial testing Topical Spray in Skin Irritation. Withdrawn.

Timeline

1 March 2016

Primary endpoint
1 June 2016

30 June 2016

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 4
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	other
Start date	1 March 2016
Primary completion	1 June 2016
Estimated completion	30 June 2016

Drugs / interventions tested

Topical Spray
Topical Gel
Saline

Conditions studied

Skin Irritation — all drugs for Skin Irritation →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 18 to 65, any sex, with Skin Irritation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine local skin safety of a topical analgesic spray containing a combination of diclofenac, methyl salicylate, menthol and compare it with a topical analgesic gel containing a combination of diclofenac, methyl salicylate, and menthol.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02400320 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 12 September 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02400320.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing